Core Viewpoint - ESSA Pharma Inc. has received overwhelming approval from its Securityholders for the acquisition by XenoTherapeutics Inc. through a statutory plan of arrangement, indicating strong support for the Transaction [1][2]. Group 1: Shareholder Approval - The special resolution for the Arrangement was approved by 99.83% of votes cast by Shareholders present at the Meeting [2]. - 99.85% of votes from all Securityholders, including those holding options and warrants, also supported the Arrangement [2]. - Excluding certain votes, 99.48% of Shareholders present voted in favor of the Arrangement [2]. Group 2: Additional Approvals - Shareholders approved the compensation for named executive officers related to the Arrangement with 99.51% support [3]. - In case the Arrangement is terminated, 99.77% of Shareholders voted for voluntary liquidation and dissolution of the Company [3]. - The appointment of PricewaterhouseCoopers LLP as the liquidator was authorized by 99.79% of votes cast [3]. Group 3: Next Steps - The Arrangement is pending approval from the Supreme Court of British Columbia, with a hearing scheduled for October 7, 2025 [4]. - Completion of the Arrangement is anticipated around October 9, 2025 [4]. Group 4: Company Background - ESSA Pharma Inc. focuses on developing novel therapies for prostate cancer treatment [5]. - XenoTherapeutics Inc. is a non-profit biotechnology company based in Massachusetts, dedicated to advancing xenotransplantation [6].
ESSA Securityholders Approve Acquisition by XenoTherapeutics